Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05915546 · ClinicalTrials.gov registry record · Phase 1

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

A Phase 1 study, sponsored by Cerevel Therapeutics.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT05915546: Completed Phase 1 study, sponsored by Cerevel Therapeutics.

NCT05915546 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05915546, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.

Interventions

  • DRUG Emraclidine

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2023-06-08
Est. Completion 2023-07-26
Phase Phase 1
Cerevel Therapeutics

21 total trials

What the finished NCT05915546 record still lists

NCT05915546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which Emraclidine is the first listed.

NCT05915546 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05915546 about?

NCT05915546 is a clinical study titled "The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants". The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.

What is the current status of trial NCT05915546?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-06-08. Estimated completion is 2023-07-26.

What interventions are being tested in trial NCT05915546?

The interventions under investigation include: Emraclidine (DRUG).

Who is sponsoring clinical trial NCT05915546?

This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05915546's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05915546, the US trial registry maintained by the National Library of Medicine. NCT05915546 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.